Detection of HIV-1(HTLV-I) pseudotypes.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Detection of HIV-1(HTLV-I) pseudotypes.

Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:107 (poster no. 65). Unique Identifier : AIDSLINE ASHM5/94348925
Lawson V; Doultree J; Lee JY; Marshall J; McPhee D; Macfarlane Burnet Centre for Medical Research, NCHVR, Fairfield,; Vic.

Abstract: The mixing of envelope glycoproteins in cells infected with two viruses may result in the formation of pseudotypes. Several studies have indicated that human immunodeficiency virus (HIV) may form pseudotypes with several viral species including human T-cell leukemia virus (HTLV-I), murine amphotropic virus and HIV-2. The resulting viral species have been shown to have an expanded host range which reflects the tropism of the acquired glycoproteins and results in more aggressive disease progression. In the majority of these studies pseudotypes have been artificially developed and the evidence for their formation based almost entirely on indirect immunological evidence. We present here a novel immunoprecipitation technique for the detection of HIV-1(HTLV-I) pseudotypes arising from HIV-1 infection of the HTLV-I transformed MT-2 cell line, as well as a technique for direct detection of pseudotypes which involves immune labelling of viral envelope glycoproteins in association with thin section electron microscopy. The HTLV-I gp46 surface glycoprotein was found in association with HIV-I core proteins in mature virus particles thus confirming previous findings and directly demonstrating pseudotype particles.

Keywords: Cell Line, Transformed Human HIV Infections/MICROBIOLOGY HIV-1/CLASSIFICATION/*PHYSIOLOGY/PATHOGENICITY HTLV-I/CLASSIFICATION/*PHYSIOLOGY/PATHOGENICITY Precipitin Tests Virulence/PHYSIOLOGY ABSTRACT
941230
M94C4302

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .